Physician profile
Richard Reamico
NPI 1174348601
$1,571.49
in general payments reported to CMS, 2019-2025
16 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 75% of Nephrology (Registered Nurse) providers received nationally (typical 2025 total: $522).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $214.61 | 2025 | Jynarque |
| Calliditas Therapeutics US INC. | $199.00 | 2025 | Tarpeyo |
| Akebia Therapeutics INC | $166.98 | 2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $164.20 | 2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $133.72 | 2025 | |
| Ardelyx, INC. | $115.75 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $106.61 | 2025 | |
| Aurinia Pharma U.S., INC. | $101.03 | 2025 | Lupkynis |
| Travere Therapeutics, INC. | $97.88 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.36 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $61.14 | 2025 | Rayaldee |
| Vifor Pharma, INC. | $50.49 | 2025 | Veltassa |
| Glaxosmithkline, LLC. | $26.43 | 2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $22.66 | 2025 | Ultomiris |
| Amgen INC. | $16.02 | 2025 | Krystexxa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $15.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Reamico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.